SCHEMBL407969

SCHEMBL407969

O=C1C=CC(=O)N1CCOCCN1C(=O)C=CC1=O

nearest known ligand 0.95

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 9/20 0.95
FAAH O00519 5/20 0.59
ALDH1A1 P00352 2/20 0.56
LMNA P02545 2/20 0.56
MAPT P10636 2/20 0.56
NPSR1 Q6W5P4 2/20 0.56
HSP90AA1 P07900 1/20 0.56
TLR9 Q9NR96 1/20 0.56
TP53 P04637 1/20 0.56
PKM P14618 1/20 0.56
HPGD P15428 1/20 0.56
XBP1 P17861 1/20 0.56
MAPK1 P28482 1/20 0.56
HTT P42858 1/20 0.56
RECQL P46063 1/20 0.56
RAB9A P51151 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
GPR35 Q9HC97 1/20 0.56
GPR55 Q9Y2T6 1/20 0.56
PTGS1 P23219 7/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9643398 0.97 MGLL (1.00) MGLLFAAHALDH1A1LMNAMAPT
SCHEMBL30009171 0.97 MGLL (1.00) MGLLFAAHALDH1A1LMNAMAPT
SCHEMBL15483488 0.97 MGLL (1.00) MGLLFAAHALDH1A1LMNAMAPT
SCHEMBL15082420 0.97 MGLL (1.00) MGLLFAAHALDH1A1LMNAMAPT
SCHEMBL140275 0.97 MGLL (1.00) MGLLFAAHALDH1A1LMNAMAPT
SCHEMBL349749 0.97 MGLL (1.00) MGLLFAAHALDH1A1LMNAMAPT
SCHEMBL19708788 0.93 MGLL (0.83) MGLLFAAHALDH1A1LMNAMAPT
SCHEMBL14996140 0.91 MGLL (0.79) MGLLFAAHALDH1A1LMNAMAPT
SCHEMBL44460 0.89 MGLL (0.76) MGLLFAAHALDH1A1LMNAMAPT
SCHEMBL15856167 0.89 MGLL (0.76) MGLLFAAHALDH1A1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113980631-A Reactive polyurethane hot melt adhesive and preparation method thereof 烟台德邦科技股份有限公司 2022-01-28 CN claimed
US-20240050587-A1 LIPOSOMES COMPRISING ANTI-LOX ANTIBODY ISTITUTO ROMAGNOLO PER LO STUDIO DEI TUMORI "DINO AMADORI" - IRST S.R.L. (IT) 2024-02-15 US disclosed
EP-4037718-A1 LIPOSOMES COMPRISING ANTI-LOX ANTIBODY Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori (I.R.S.T.) S.R.L. (IT) 2022-08-10 EP disclosed
WO-2016143647-A1 PROCESS FOR PRODUCING LOW-CONCENTRATION GEL USING GEL-PRECURSOR CLUSTERS, AND GEL OBTAINED BY SAID PRODUCTION PROCESS 国立大学法人 東京大学 2016-09-15 WO disclosed
US-9267005-B2 Flexible maleimide polymer and method for preparing the same INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) 2016-02-23 US disclosed
US-8895759-B2 Intermediates useful in the preparation of maleimide functionalized polymers NEKTAR THERAPEUTICS (US) 2014-11-25 US disclosed
US-20140309168-A1 MODIFIED PEPTIDES AND PROTEINS AMIDEBIO, LLC (US) 2014-10-16 US disclosed
US-20140155457-A1 Method of Relieving, Improving, Preventing or Treating Xerostomia SUNBIO INC. (KR) 2014-06-05 US disclosed
US-20140128619-A1 Intermediates Useful in the Preparation of Maleimide Functionalized Polymers NEKTAR THERAPEUTICS (US) 2014-05-08 US disclosed
US-8653286-B2 Intermediates useful in the preparation of maleimide functionalized polymers NEKTAR THERAPEUTICS (US) 2014-02-18 US disclosed
US-8258324-B2 Intermediates useful in the preparation of maleimide functionalized polymers NEKTAR THERAPEUTICS (US) 2012-09-04 US disclosed
US-20120064061-A1 ADHESIVE COMPOSITION COMPRISING TANNIN, POLY(ETHYLENE GLYCOL), AND WATER, LOWER ALCOHOL OR MIXTURE THEREOF INNOTHERAPY INC. (KR) 2012-03-15 US disclosed
US-20120004422-A1 Intermediates Useful in the Preparation of Maleimide Functionalized Polymers NEKTAR THERAPEUTICS (US) 2012-01-05 US disclosed
US-8039579-B2 Intermediates useful in the preparation of maleimide functionalized polymers NEKTAR THERAPEUTICS (US) 2011-10-18 US disclosed
US-20100261841-A1 Intermediates Useful in the Preparation of Maleimide Functionalized Polymers NEKTAR THERAPEUTICS (US) 2010-10-14 US disclosed
US-7790835-B2 Water soluble, non-peptidic polymer covalently attached to a Diels-Alder bicyclic or tricyclic imide ring; chemical intermediates NEKTAR THERAPEUTICS (US) 2010-09-07 US disclosed
EP-2114998-A1 NOVEL MULTIMERIC MOLECULES, METHOD FOR PREPARING SAME AND USE THEREOF IN THE PREPARATION OF DRUGS Centre National de la Recherche Scientifique (FR) 2009-11-11 EP disclosed
WO-2008110695-A1 NOVEL MULTIMERIC MOLECULES, METHOD FOR PREPARING SAME AND USE THEREOF IN THE PREPARATION OF DRUGS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2008-09-18 WO disclosed
EP-0975669-A1 CALCITONIN RECEPTOR-BINDING PEPTIDES Diatide, Inc. (US) 2000-02-02 EP disclosed
WO-1998049196-A1 CALCITONIN RECEPTOR-BINDING PEPTIDES DIATIDE, INC. (US) 1998-11-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140155457-A1 Method of Relieving, Improving, Preventing or Treating Xerostomia GLA, LPO, MUC1 MGLL 239/4885FAAH 930/4885ALDH1A1 2041/4885
US-20120064061-A1 ADHESIVE COMPOSITION COMPRISING TANNIN, POLY(ETHYLENE GLYCOL), AND WATER, LOWER ALCOHOL OR MIXTURE THEREOF EPCAM, ICAM1, VCAM1 MGLL 352/4885FAAH 260/4885ALDH1A1 620/4885
US-20140128619-A1 Intermediates Useful in the Preparation of Maleimide Functionalized Polymers DERA, MMAB, PAICS MGLL 3710/4885FAAH 4109/4885ALDH1A1 74/4885
US-20120004422-A1 Intermediates Useful in the Preparation of Maleimide Functionalized Polymers DERA, MMAB, PAICS MGLL 3710/4885FAAH 4109/4885ALDH1A1 74/4885
US-20140309168-A1 MODIFIED PEPTIDES AND PROTEINS IAPP, VIP, ENPEP MGLL 2869/4885FAAH 2984/4885ALDH1A1 4652/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.